
The study revealed FGF1 utilizes a different pathway, PDE4, to control blood glucose, providing a parallel system for patients with insulin resistance. This finding opens doors for drug development and fundamental research in managing high blood sugar and insulin resistance. The researchers aim to explore ways to enhance PDE4 activity through FGF1 modifications for better diabetes management.
Like
Save
Share